S Xu, B Jiang, KA Maitland, H Bayat, J Gu, JL Nadler, S … - Diabetes, 2006 - Am Diabetes Assoc Arachidonic acid metabolites, some of which may activate thromboxane A 2 receptors (TPr) and
contribute to the development of diabetes complications, including nephropathy, are elevated
in diabetes. This study determined the effect of blocking TPr with S18886 or inhibiting ... Cited by 38 - Related articles - BL Direct - All 7 versions
- ►ahajournals.org A Zuccollo, C Shi, R Mastroianni, KA Maitland-Toolan, … - Circulation, 2005 - Am Heart Assoc Methods and Results— Diabetes mellitus was induced in apoE –/– mice with streptozotocin and
was treated or not with S18886 (5 mg · kg –1 · d –1 ). After 6 weeks, aortic lesion area was increased
>4-fold by diabetes in apoE –/– mice, associated with similar increases in serum glucose ... Cited by 44 - Related articles - All 9 versions
K Šebeková, T Eifert, A Klassen, A Heidland, K Amann - Diabetes, 2007 - Am Diabetes Assoc Thromboxane A 2 (TxA 2 ) is assumed to contribute to the development of diabetes
complications, including nephropathy. We investigated whether the selective thromboxane-prostanoid
endoperoxide receptor antagonist, S18886, ameliorates renal damage in ... Cited by 11 - Related articles - BL Direct - All 5 versions
- ►physiology.org [PDF] F Michel, S Simonet, C Vayssettes- … - American Journal of …, 2007 - Am Physiological Soc Page 1. 1 Altered TP-receptor function in isolated perfused kidneys of non-diabetic
and diabetic Apo E-deficient mice Frédéric Michel, Serge Simonet, Christine
Vayssettes-Courchay, Florence Bertin, Patricia Sansilvestri-Morel ... Cited by 5 - Related articles - BL Direct - All 3 versions
- ►ahajournals.org M Zhang, Y Dong, J Xu, Z Xie, Y Wu, P Song, M … - Circulation …, 2008 - Am Heart Assoc Thromboxane A 2 receptor (TPr) stimulation induces cellular hypertrophy in vascular smooth
muscle cells (VSMCs); however, regulation of VSMC hypertrophy remains poorly
understood. Here we show that TPr stimulation activates AMP-activated kinase (AMPK), ... Cited by 8 - Related articles - All 5 versions
NF Worth, CL Berry, AC Thomas, JH Campbell - Atherosclerosis, 2005 - Elsevier The right iliac artery of 96 rabbits (8 groups, n = 12/group) was balloon injured, then the animals
were fed a cholesterol-enriched diet for 6 weeks. In Groups 1–4, concomitant oral administration
of S18886 at 5 mg/kg/day over the 6-week-period reduced the intima to media ratio of ... Cited by 39 - Related articles - All 14 versions
- ►onlinejacc.org L Belhassen, G Pelle, JL Dubois-Rande, S Adnot - Journal of the American …, 2003 - Elsevier Twenty patients with stable CAD treated with 100 mg/day aspirin were evaluated in a
randomized, double-blinded, placebo-controlled study. Twelve patients received a single oral
dose of 10 mg S 18886, and eight patients received placebo. Before and 60 min after a ... Cited by 80 - Related articles - BL Direct - All 12 versions
[CITATION] S18886, a thromboxane A 2 receptor antagonist, prevents occurrence of …
P Gelosa, E Nobili, A Gianella, V Blanc-Guillemaud, L … - Cerebrovasc Dis, 2007 Cited by 5 - Related articles
P Gaussem, JL Reny, C Thalamas, N … - … of Thrombosis and …, 2005 - interscience.wiley.com Summary. Objectives and patients: We conducted a multicenter double-blind
pharmacokinetic/pharmacodynamic (PK/PD) study of the new oral thromboxane receptor antagonist
S18886 in 30 patients with peripheral artery disease, who were randomized to receive ... Cited by 33 - Related articles - All 3 versions
- ►nih.gov SJ Wilson, K McGinley, AJ Huang, EM Smyth - Biochemical and biophysical …, 2007 - Elsevier Isoprostanes are free radical catalyzed products of arachidonic acid that are elevated in
pro-oxidant disease states. Two isoprostanes, 8-isoprostaglandin F 2α (iPF 2α III) and 8-isoprostaglandin
E 2 (iPE 2 III), act at the receptor for thromboxane A 2 (the TP) to mediate pro-atherogenic ... Cited by 4 - Related articles - All 6 versions
